List of Excipients in Branded Drug BETAXOLOL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	BENZALKONIUM CHLORIDE
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	EDETATE DISODIUM
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	HYDROCHLORIC ACID
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	SODIUM CHLORIDE
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	SODIUM HYDROXIDE
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	WATER

Generic Drugs Containing BETAXOLOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
KVK-TECH INC	betaxolol hydrochloride	10702-013	ANHYDROUS LACTOSE
KVK-TECH INC	betaxolol hydrochloride	10702-013	CELLULOSE, MICROCRYSTALLINE
KVK-TECH INC	betaxolol hydrochloride	10702-013	HYPROMELLOSE 2910
KVK-TECH INC	betaxolol hydrochloride	10702-013	POLYETHYLENE GLYCOL 400
KVK-TECH INC	betaxolol hydrochloride	10702-013	POLYSORBATE 80
KVK-TECH INC	betaxolol hydrochloride	10702-013	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in BETAXOLOL HYDROCHLORIDE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE 2910
1	POLYETHYLENE GLYCOL 400
1	POLYSORBATE 80
1	SODIUM STARCH GLYCOLATE TYPE A POTATO

Excipient Strategy and Commercial Opportunities for Betaxolol Hydrochloride

Last updated: March 1, 2026

What are the key excipient considerations for Betaxolol Hydrochloride formulations?

Betaxolol hydrochloride is a selective beta1-adrenergic blocker used primarily for ocular applications in glaucoma and systemic hypertension. Formulation success depends heavily on excipient selection to ensure stability, bioavailability, and patient compliance.

Typical excipients for Betaxolol Hydrochloride formulations

• Buffers: Phosphate buffers maintain pH around 4.5–6.0, optimal for stability.
• Preservatives: Benzalkonium chloride is common in eye drops for antimicrobial preservation.
• Viscosity modifiers: Hydroxypropyl methylcellulose (HPMC) enhances ocular residence time.
• Solubilizers: Surfactants like polysorbate 80 improve solubility if necessary.
• Osmotic agents: Sodium chloride adjusts tonicity.
• Chelating agents: EDTA prevents metal ion-catalyzed degradation.

Formulation types and excipient implications

• Ophthalmic solutions: Require preservatives, viscosity agents, and buffering systems.
• Systemic tablets: Use excipients like fillers (lactose, microcrystalline cellulose), disintegrants (corn starch), and binders (povidone).

What commercial opportunities exist based on excipient strategies?

Differentiation via excipient innovation

• Developing preservative-free formulations addresses patient allergies and regulatory pressures, expanding market reach.
• Utilizing novel viscosity enhancers can improve ocular drug retention, potentially increasing dosing intervals.
• Incorporating bio-compatible, long-acting excipients can support sustained-release formulations, opening new therapeutic segments.

Regulatory and market trends

• Regulatory agencies (FDA, EMA) demand excipient transparency, especially for preservatives and excipient impurities.
• The ocular drug market in glaucoma is projected to grow at a CAGR of 4% through 2030, driven by aging populations and unmet needs.
• Systemic beta-blockers like Betaxolol face competition from newer agents with better side-effect profiles; excipient improvements can provide differentiation.

Manufacturing and supply chain considerations

• Sourcing high-quality excipients aligned with regulatory standards (USP, EP) ensures compliance.
• Scale-up of innovative excipients can reduce costs and improve margins.
• Partnerships with excipient manufacturers facilitate access to customized formulations.

How can excipient choices influence commercial success?

• Enhanced stability extends shelf life, reduces waste, and improves supply chain reliability.
• Better tolerability due to excipient selection can increase patient adherence, improving market penetration.
• Differentiated formulations with novel excipients can command premium pricing.
• Regulatory approvals for excipient modifications can open new markets or indicate viability for product line extension.

Summary

Formulating Betaxolol Hydrochloride requires strategic excipient selection tailored to its route of administration and therapeutic target. Innovation in excipient use—particularly preservative-free, sustained-release, or bio-compatible options—offers avenues for differentiation and market expansion. The growing prevalence of glaucoma and systemic hypertension underscores the need for efficient, patient-friendly formulations, presenting commercial opportunities for companies capable of navigating regulatory, manufacturing, and supply chain complexities.

---

Key Takeaways

• Excipient selection impacts stability, bioavailability, tolerability, and regulatory compliance for Betaxolol Hydrochloride.
• Differentiated formulations, especially preservative-free and sustained-release options, can capture market share.
• Regulatory trends favor transparent, well-characterized excipients, influencing formulation choices.
• Market growth in ocular and systemic beta-blocker use rewards innovation in excipient strategies.
• Successful formulation combines technical stability with commercial viability through strategic excipient use.

---

FAQs

1. What excipient is critical for maintaining Betaxolol Hydrochloride stability?
Phosphate buffers maintain solution pH and prevent degradation.

2. How does preservative choice affect Betaxolol ophthalmic formulations?
Preservatives like benzalkonium chloride provide antimicrobial activity but can cause corneal toxicity; preservative-free alternatives improve tolerability.

3. Can excipient innovation extend Betaxolol's market lifespan?
Yes. Including sustained-release excipients can create novel formulations that meet unmet needs and differentiate products.

4. Are there regulatory challenges with new excipients in Betaxolol formulations?
Yes. New excipients require extensive safety data and regulatory approval, which can delay product launches.

5. What are emerging trends in Betaxolol formulation development?
Moving towards preservative-free, long-acting, and patient-friendly formulations. Use of bio-compatible excipients is increasing.

---

References

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Basic Principles of Drug Development and Registration.
[2] European Medicines Agency. (2022). Guideline on quality of ophthalmic preparations.
[3] MarketWatch. (2023). Glaucoma drug market size and forecasts.
[4] WHO. (2019). Guide to Good Prescribing for Eye Drops.
[5] USP Monograph. (2022). Betaxolol Hydrochloride.